The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

Improved 12-month oral function post concurrent chemoradiotherapy (CRT) for head and neck cancer (HNC)

Print

Sub-category:
Head and Neck Cancer

Category:
Head and Neck Cancer

Meeting:
2003 ASCO Annual Meeting

Session Type and Session Title:
Poster Discussion, Head and Neck Cancer

Abstract No:
2004

Citation:
Proc Am Soc Clin Oncol 22: 2003 (abstr 2004)

Author(s):
M. A. List, D. Haraf, R. Egan, P. Bilir, B. Mittal, A. Argiris, F. Rosen, K. Stenson, J. Dignam, E. E. Vokes; University of Chicago, Chicago, IL; Northwestern Memorial Hospital, Chicago, IL; University of Illinois at Chicago, Chicago, IL

Abstract:

This paper examines factors associated with 12-month non-oral feeding (NPO) in advanced stage HNC patients post concurrent chemoradiotherapy (CRT). While these regimens appear successful in improving disease control and survival as well as function/quality of life (QOL), data also document significant long-term dysfunction in at least a subgroup of patients. Of particular concern are those who remain feeding tube dependent upwards of a year post treatment. Prospective QOL/functional data were collected on 251 patients treated on one of four sequential CRT trials conducted across four Chicago institutions (I-IV). Trials 1 & 2 (Group A) included five cycles of twice daily radiation with concurrent CRT (5-FU, hydroxyurea and paclitaxel). Trials 3 & 4 (Group B) added two cycles of induction chemotherapy to the above regimen. Pre-treatment QOL/functional data and 12-month diet data were available on 172 of 210 patients alive at 12 months. In spite of the addition of induction chemotherapy only 6% of patients in Group B were unable to take anything by mouth at 12 months compared to 19% of patients in Group A. By univariate analyses other pre-treatment variables associated with increased risk (p<.05) of NPO status at 12 months included: larger tumor, feeding tube, restricted diet, difficulty being understood, sticky saliva, hoarseness, poorer overall performance status, decreased head & neck well being (FACT subscale), African American race, lower income and institution I. Group remained significant in multivariate analyses controlling for all other variables. While further investigation is warranted, differences in CRT regimens, increased use of sophisticated radiation techniques, changes in supportive care, and more proactive swallowing intervention may have contributed to improvement in long term eating ability. In conclusion, the decline in the number of patients with severe oral dysfunction to only 6% supports the continued development of aggressive regimens focusing on survival.


  Associated Presentation(s):

    

1. Improved 12-month oral function post concurrent chemoradiotherapy (CRT) for head and neck cancer (HNC)

Meeting: 2003 ASCO Annual Meeting
Presenter: Marcy A List, PhD
Session: Head and Neck Cancer (Poster Discussion)


  Other Abstracts in this Sub-Category:

    

1. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: A factorial study

Meeting: 2003 ASCO Annual Meeting   Abstract No: 1990   First Author: D. L. W. Kwong
Category: Head and Neck Cancer

    

2. A randomized study of concomitant radiotherapy with cisplatin or carboplatin versus radiotherapy alone in patients with locally advanced non-nasopharyngeal head and neck cancer. A Hellenic Cooperative Oncology Group (HeCOG) phase III study

Meeting: 2003 ASCO Annual Meeting   Abstract No: 1991   First Author: G. Fountzilas
Category: Head and Neck Cancer

    

3. Preliminary results of TROG 98.02 - a randomized phase II study of 5-fluorouracil, cisplatin and radiation versus tirapazamine, cisplatin and radiation for advanced squamous cell carcinoma of the head and neck

Meeting: 2003 ASCO Annual Meeting   Abstract No: 1992   First Author: D. Rischin
Category: Head and Neck Cancer

    

More...


  Abstracts by M. A. List:

    

1. Performance and side effect evaluation of sequentially reduced radiotherapy doses in a phase II trial of induction chemotherapy (IndCT) followed by concomitant chemoradiotherapy (CTX) for advanced head and neck cancer (HNC).

Meeting: 2006 ASCO Annual Meeting   Abstract No: 5558   First Author: M. A. List
Category: Head and Neck Cancer

    

2. Sequential evaluation of reduced radiotherapy doses in a phase II trial of induction chemotherapy (IndCT) followed by concomitant chemoradiotherapy (CTX) for advanced head and neck cancer (HNC).

Meeting: 2006 ASCO Annual Meeting   Abstract No: 5528   First Author: E. E. Vokes
Category: Head and Neck Cancer

    

3. The impact of induction chemotherapy on subsequent concurrent chemoradiotherapy (CRT) related side effects, function & quality of life (QOL) in head and neck cancer (HNC).

Meeting: 2004 ASCO Annual Meeting   Abstract No: 5537   First Author: M. A. List
Category: Head & Neck Cancer - Head and Neck Cancer

    

More...


  Presentations by M. A. List:

    

1. Performance and side effect evaluation of sequentially reduced radiotherapy doses in a phase II trial of induction chemotherapy (IndCT) followed by concomitant chemoradiotherapy (CTX) for advanced head and neck cancer (HNC).

Meeting: 2006 ASCO Annual Meeting
Presenter: Marcy A List, PhD
Session: Head and Neck Cancer (General Poster Session)

    

2. The impact of induction chemotherapy on subsequent concurrent chemoradiotherapy (CRT) related side effects, function & quality of life (QOL) in head and neck cancer (HNC).

Meeting: 2004 ASCO Annual Meeting
Presenter: Marcy A. List, PhD
Session: Head and Neck Cancer (Poster Discussion)

    

3. Head and Neck Cancer: Which Treatment Approach Best Serves Your Patient?

Meeting: 2003 ASCO Annual Meeting
Speaker: Marcy A List, PhD
Session: Head and Neck Cancer: Which Treatment Approach Best Serves Your Patient? (Education Session)

    

More...


  Educational Book Manuscripts by M. A. List:

    

No items found.




 
2318 Mill Road, Suite 800, Alexandria, VA 22314   |   phone: (571) 483-1300
© 2005-2009 American Society of Clinical Oncology (ASCO).  All rights reserved worldwide.